The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors ...

SAN ANTONIO -- The antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) failed to outperform chemotherapy as first ...

Giredestrant lowered the risk of disease recurrence or death by 30%, compared with standard-of-care endocrine therapy, ...

Breast cancer comes with many variables. A pair of powerful genomic tests can help women and their care teams make ...

Lumpectomy has been the standard of care for low-risk, early-stage breast cancer, but now cryoablation — freezing cancer ...

Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared ...

Roche Holding shares rose 2.1% Wednesday after the Swiss drugmaker reported positive results from a new study of an ...

A recent breast cancer vaccine brings good news for women. The jab could help prevent Triple-negative breast cancer (TNBC) ...

Jessie said she was diagnosed in March with early-stage breast cancer, a diagnosis that came just days before she was set to ...

In a Phase 1 trial, women responded well to the novel vaccine. More research is needed to determine whether it can stop the ...

Cleveland Clinic researchers are presenting final Phase I data from their novel study of a vaccine aimed at preventing triple ...

Patients with stage 1 or 2, hormone receptor (HR)-negative breast cancer had similar five-year rates of locoregional ...